More evolution of the evidence in asthma disease management--SMART versus GOAL clinical trials debate the cost-benefit of LABA while the value of leukotriene modifiers, particularly montelukast, is uncertain.

Download in:

• JSON
• RDF
• N3/Turtle
• N-Triples

View as

• Triples